Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Exclusion Criteria

• - Known history of allergy or reaction to any component of AZD7442 (AZD8895 + AZD1061).
• - History of infection with SARS or Middle East Respiratory Syndrome.
• - Positive SARSCoV-2 result based on available data at screening or at Day 1.
• - Any clinical signs and symptoms consistent with Corona virus disease 2019 (COVID-19), eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
• - History of clinically significant bleeding disorder.
• - Active infection with hepatitis B or C or positive test for hepatitis C or for hepatitis B surface antigen at screening.
• - Immunodeficiency due to illness, including HIV infection, or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone.
• - Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study
• -Any prior receipt of another mAb indicated for the prevention or treatment of SARS CoV-2 or COVID-19.
• - Receipt of a mAb within 6 months or 5 antibody half-lives.
• - Receipt of a COVID-19 vaccination ≤ 14 days before IMP administration (Day 1) or plan to receive a COVID-19 vaccination ≤ 14 days after IMP dose (such participants can subsequently be included in the study once they have reached > 14 days after their last dose of vaccine).